Congress Materials

Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

I am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
SelectI am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
I am a U.S. Patient / CaregiverNo, go back to the patient portal
SelectI am a U.S. Patient / CaregiverNo, go back to the patient portal
Non-US residents click here.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.
Poster
Costa LJ, LeBlanc TW, Tesch H, Sonneveld P, Kyle R, Sinyavskaya L, Hlavacek P, Meche A, Ren J, Schepart A, Aydin D, DiBonaventura M June 9, 2023 EHA2023 Hematology

An Indirect Comparison of Elranatamab’s (ELRA) Objective Response Rate (ORR) From MagnetisMM-3 (MM-3) Versus Real-World External Control Arms in Triple-Class Refractory (TCR) Multiple Myeloma (MM)

View Presentation View Abstract Plain Language Summary
Poster
Flore Sicre de Fontbrune, Mony Fahd, Edouard Forcade, Suzane Tavitian, Cécile Moluçon Chabrot, Fiorenza Barraco, Yosr Hicheri, Delphine Lebon, Sébastien Maury, Anne-Lise Menard, Barbara Mozejko - Pastewka, Kevin D Wolter, Bruno Valtier, Thierry Leblanc, Régis Peffault de Latour June 9, 2023 EHA2023 Anemia

ATGAM Efficacy and Safety in Moderate and Severe Acquired Aplastic Anemia: Outcome of a Large Multicenter Cohort of 634 Children and Adults From the French Authorization for Temporary Use Surveillance Program

View Presentation
Poster
Leleu X, Raje N, Lesokhin A, Mohty M, Nooka AK, Leip E, Sullivan ST, Viqueira A, Manier S June 9, 2023 EHA2023 Hematology

Efficacy and Safety of Elranatamab by Age and Frailty in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): A Subgroup Analysis From MagnetisMM-3

View Presentation View Abstract Plain Language Summary
Poster
Touzeau C, Bahlis N, Maisel C, Karlin L, Varshavsky-Yanovsky AN, Leip E, Conte U, Viqueira A, Larson S June 9, 2023 EHA2023 Hematology

Efficacy and Safety of Elranatamab in High-Risk Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis From MagnetisMM-3

View Presentation View Abstract Plain Language Summary
Poster
Manier S, Lesokhin AM, Mohty M, Niesvizky R, Maisel C, Arnulf B, Larson SM, Varshavsky-Yanovsky AN, Leleu X, Karlin L, Vesole DH, Bahlis NJ, Fernández de Larrea C, Raje N, Leip E, Sullivan S, Elmeliegy M, Viqueira A, Nooka AK June 9, 2023 EHA2023 Hematology

Efficacy and Safety of Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma and Prior B-Cell Maturation Antigen (BCMA)-Directed Therapies: A Pooled Analysis From MagnetisMM studies

View Presentation View Abstract Plain Language Summary
Poster
Leleu X, Iida S, Landgren O, Lesokhin AM, Leip E, Kudla A, Finn G, Qiu L June 9, 2023 EHA2023 Hematology

Elranatamab Monotherapy or in Combination With Daratumumab vs Daratumumab + Pomalidomide + Dexamethasone for Patients With Relapsed/Refractory Multiple Myeloma: Phase 3 MagnetisMM-5 Study, Part 2

View Presentation
Poster
Rodriguez-Otero P, Quach H, Weisel K, Viqueira A, Wang S-W, Hamilton PT, Xie T, O’Brien T, Bahlis NJ June 9, 2023 EHA2023 Hematology

Genomic Analysis to Identify Determinants of Inherent Response and Resistance to Elranatamab in MagnetisMM-3 Cohort A

View Presentation View Abstract Plain Language Summary
Poster
Weisel K, Bahlis N, Rodriguez-Otero P, Viqueira A, Wang S-W, Sathiah S, Robinson DM, O’Brien T, Quach H June 9, 2023 EHA2023 Hematology

Identification of Cytokines Associated With Response and Cytokine Release Syndrome – Analysis of MagnetisMM-3 Cohort A

View Presentation View Abstract Plain Language Summary
Poster
Chiara Federici, Senuyesertel, Samantha J. Braxton, Gabrielle Combs, Madelyn Spehn, Kara Opheim, Pavel Kovshovik, John Zak, Xin Geng, Umut A Gurkan June 9, 2023 EHA2023 Sickle Cell Disease

In vitro comparison of the effects of Inclacumab vs Crizanlizumab on reducing Endothelial Adhesion of Red Blood Cell in Standardized Microfluidic platform

View Presentation
Poster
Hlavacek P, Mol I, Hu Y, Cappelleri JC, Chu H, Aydin D June 9, 2023 EHA2023 Hematology

Indirect Treatment Comparison of Elranatamab With Belmaf, Sel-Dex, and Real-World Physician’s Choice of Treatment in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

View Presentation